Standout Papers

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer 2011 2026 2016 2021 1.7k
  1. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011)
    José Baselga, Javier Cortés et al. New England Journal of Medicine
  2. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (2015)
    Sandra M. Swain, José Baselga et al. New England Journal of Medicine
  3. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (2017)
    Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine
  4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study (2013)
    Sandra M. Swain, Sung‐Bae Kim et al. The Lancet Oncology

Immediate Impact

6 by Nobel laureates 29 from Science/Nature 89 standout
Sub-graph 1 of 22

Citing Papers

Mechanisms driving the immunoregulatory function of cancer cells
2023 Standout
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
2022 Standout
1 intermediate paper

Works of Emma Clark being referenced

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
2017 Standout
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
2015 Standout

Author Peers

Author Last Decade Papers Cites
Emma Clark 4917 1690 241 2070 48 6.0k
Mark Benyunes 4461 1459 423 1960 37 5.9k
Cristina Oliva 4700 1995 217 1290 66 6.1k
Graham Ross 7823 2140 382 2831 42 9.0k
Giulia Bianchi 4641 1485 433 1806 126 5.9k
José Luiz Pedrini 4021 1404 282 1512 25 4.9k
David Miles 5878 2119 225 2655 92 8.2k
Laslo Roman 4232 1285 507 1324 31 5.0k
Edith A. Perez 3232 788 199 1520 87 4.5k
Roberto Hegg 6369 2253 394 1534 80 8.0k
Mark S. Berger 4535 1213 397 2021 67 6.8k

All Works

Loading papers...

Rankless by CCL
2026